Piperazine bisferulate
CAS 96585-18-1
Piperazine bisferulate (CAS 96585-18-1) is a pharmaceutical compound with 0 bioactivity targets and 9 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Piperazine bisferulate is linked to DTXSID00242347 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Piperazine bisferulate used for in pharmaceutical contexts?
Piperazine bisferulate (CAS 96585-18-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Piperazine bisferulate?
Piperazine bisferulate has 9 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abnormal behaviour, Dysarthria, Glomerulonephritis chronic, Hallucination, Hypokalaemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Piperazine bisferulate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Piperazine Bisferulate with EU status "permitted".
What clinical phase is Piperazine bisferulate in?
No phase 1-4 clinical development badge is rendered for Piperazine bisferulate because the matched compound identifier rows do not contain a max-phase value.